Mylan launches generic version of Prandin

PITTSBURGH — Mylan on Thursday announced that its subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin. The drug is used to improve glycemic control in adults with Type 2 diabetes mellitus.

Repaglinide tablets in 0.5 mg, 1 mg and 2 mg had sales in the United States of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

 

Login or Register to post a comment.